Mont. Jury Awards $3.2M In 1st Zometa Jaw Injury Case To Go To Verdict
November 2nd, 2009
No comments
In the first bisphosphonate case to go to verdict, a Montana state court jury on Oct. 21 awarded a plaintiff $3.2 million after finding that Novartis Pharmaceuticals Corp. was negligent in failing to warn her doctors of the risks of its Zometa bone-loss prevention drug and causing her osteonecrosis of the jaw (ONJ) (Peggy L. Stevens v. Novartis Pharmaceuticals Corporation, No. DV-08-100, Mont. Dist., 4th Dist., Missoula Co.).